An investigational drug for glioblastoma more than doubled survival and progression-free time compared to standard rates, reported a new study published in Nature Communications. Glioblastoma is the ...
The company reports the drug showed “clinically meaningful improvements” in overall survival.
Welireg significantly improved quality-adjusted survival time over Afinitor in advanced renal cell carcinoma, with a mean Q-TWiST of 17.47 months versus 14.81 months. The relative gain in Q-TWiST with ...
A new independent clinical trial shows that Safeback’s SBX system can increase survival time almost fivefold for avalanche burial victims. There’s one worst case scenario in backcountry skiing that ...